Document is current
Any future updates will be listed below
-
Authors
Sementsov, Mark https://orcid.org/0009-0006-8591-2237
Ott, Leonie https://orcid.org/0000-0002-6308-0242
Kött, Julian https://orcid.org/0000-0003-2073-3909
Sartori, Alexander https://orcid.org/0009-0001-7741-7555
Lusque, Amelie
Degenhardt, Sarah https://orcid.org/0000-0002-0626-8281
Segier, Bertille https://orcid.org/0009-0005-3492-3780
Heidrich, Isabel
Volkmer, Beate https://orcid.org/0000-0001-9218-8650
Greinert, Rüdiger
Mohr, Peter
Simon, Ronald
Stadler, Julia-Christina
Irwin, Darryl https://orcid.org/0000-0003-4842-6708
Koch, Claudia
Andreas, Antje
Deitert, Benjamin https://orcid.org/0000-0003-2794-0003
Thewes, Verena
Trumpp, Andreas https://orcid.org/0000-0002-6212-3466
Schneeweiss, Andreas
Belloum, Yassine
Peine, Sven
Wikman, Harriett https://orcid.org/0000-0001-6862-0888
Riethdorf, Sabine https://orcid.org/0000-0003-0028-5643
Schneider, Stefan W https://orcid.org/0000-0002-4679-7137
Gebhardt, Christoffer https://orcid.org/0000-0001-7090-9584
Pantel, Klaus https://orcid.org/0000-0001-5736-2772
Keller, Laura https://orcid.org/0000-0002-1786-9760
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe (70114705)
EC | ERC | HORIZON EUROPE European Research Council (834974)
Bundesministerium für Bildung und Forschung (031B0843D)
Fondation de France
Institut National de la Santé et de la Recherche Médicale (Plan Cancer 2014-2019)
- License Information
-
More Information
Article History
Received: 12 September 2023
Revised: 3 May 2024
Accepted: 14 May 2024
First Online: 19 June 2024
Disclosure and competing interests statement
: MS, LO, JK, AL, BS, IH, JCS, AA, YB, HW, BD, SR, SD, BV, GR, RS, SP, KP, and LK declare no competing interest. AS and DI are employees of Agena Bioscience and hold shares of Mesa Labs. PM declares participation in Data Safety Monitoring Advisory Boards for MSD, Pierre Fabre, GSK, Roche, Bristol Myers Squibb, Novartis, Sanofi, Beiersdorf, Almirall, Hermal, AMGEN, and Sun-Pharma. CG is a member of the advisory board of, and has received honoraria and travel expenses from Almirall, Amgen, Beiersdorf, BioNTech, Bristol-Myers Squibb, Immunocore, Janssen, MSD Sharp & Dohme, Novartis, Pierre-Fabre, Roche, Sanofi Genzyme, SUN Pharma, Sysmex, ouside the submitted work; CG holds shares of Dermagnostix.
